Hikma Pharmaceuticals PLC (LON:HIK)
1,531p+0.07%
Spriggl Score: Good— sign in to explore; full breakdown with Premium
Last 30 trading days
Spriggl AI Verdict
“Cheap on most measures with a growing dividend; margin recovery story awaits H1 2026 confirmation.”
Sign up free to read the full investment thesis, bull case, bear case and what to watch.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injecta…
- Sector:
- Healthcare
- Industry:
- Drug Manufacturers - Specialty & Generic
- Market Cap:
- £3.1B
Recent dividends
- 19 Mar 202636.48p
- 14 Aug 202527.35p
- 20 Mar 202537.21p
Get the full Spriggl analysis — free
A free Spriggl account gets you the screener, a watchlist, AI verdicts and a free full report every day — across Hikma Pharmaceuticals PLC and 1,500+ UK and US stocks. The full score breakdown and AI analysis come with Premium.
Start free